{"pmid":32399393,"pmcid":"PMC7215148","title":"The potential role of TNFalpha in 2019 novel coronavirus pneumonia.","text":["The potential role of TNFalpha in 2019 novel coronavirus pneumonia.","The outbreak of 2019 novel coronavirus has spread rapidly in multiple countries. We report the first case of 2019-nCoV infection in a patient with Ankylosing Spondylitisthe (AS), who was a biological agent (anti-TNFalpha) user in Wenzhou, China, and describe the clinical course and management of the case.","Respir Med Case Rep","Ye, Wenjing","Lu, Saisai","Xue, Ali","32399393"],"abstract":["The outbreak of 2019 novel coronavirus has spread rapidly in multiple countries. We report the first case of 2019-nCoV infection in a patient with Ankylosing Spondylitisthe (AS), who was a biological agent (anti-TNFalpha) user in Wenzhou, China, and describe the clinical course and management of the case."],"journal":"Respir Med Case Rep","authors":["Ye, Wenjing","Lu, Saisai","Xue, Ali"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399393","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.rmcr.2020.101087","keywords":["2019 novel coronavirus","rheumatic disease","tumor necrosis factor-alpha"],"locations":["Wenzhou","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666865855043993601,"score":9.490897,"similar":[{"pmid":32476306,"title":"Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report.","text":["Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report.","The neurologic manifestations concerning coronavirus disease 2019 (COVID-19) are highly penetrated. Anosmia and ageusia are one of the common acute neurologic symptoms, which develop in the early stage of COVID-19. However, it is not reported that how immunosuppressive agents affect these symptoms. We report olfactory and gustatory dysfunctions in a patient with ankylosing spondylitis (AS) treated with etanercept during COVID-19. A 53-year-old female showing AS controlled with tumor necrosis factor-alpha inhibitor, etanercept, had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, presenting cough and rhinorrhea. One month after diagnosis, she complained about hyposmia and hypogeusia two days before the seronegative conversion of SARS-CoV-2, which were confirmed by a neurological examination. We speculate that the etanercept may have delayed the development of olfactory and gustatory dysfunction in the patient.","J Korean Med Sci","Lee, Jong Mok","Lee, Sang Jin","32476306"],"abstract":["The neurologic manifestations concerning coronavirus disease 2019 (COVID-19) are highly penetrated. Anosmia and ageusia are one of the common acute neurologic symptoms, which develop in the early stage of COVID-19. However, it is not reported that how immunosuppressive agents affect these symptoms. We report olfactory and gustatory dysfunctions in a patient with ankylosing spondylitis (AS) treated with etanercept during COVID-19. A 53-year-old female showing AS controlled with tumor necrosis factor-alpha inhibitor, etanercept, had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, presenting cough and rhinorrhea. One month after diagnosis, she complained about hyposmia and hypogeusia two days before the seronegative conversion of SARS-CoV-2, which were confirmed by a neurological examination. We speculate that the etanercept may have delayed the development of olfactory and gustatory dysfunction in the patient."],"journal":"J Korean Med Sci","authors":["Lee, Jong Mok","Lee, Sang Jin"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476306","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3346/jkms.2020.35.e201","keywords":["neurologic manifestations","severe acute respiratory syndrome coronavirus 2","tumor necrosis factor-alpha"],"topics":["Case Report"],"weight":1,"_version_":1668532089561022464,"score":148.81717},{"pmid":32004427,"pmcid":"PMC7092802","title":"First Case of 2019 Novel Coronavirus in the United States.","text":["First Case of 2019 Novel Coronavirus in the United States.","An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient's initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.","N Engl J Med","Holshue, Michelle L","DeBolt, Chas","Lindquist, Scott","Lofy, Kathy H","Wiesman, John","Bruce, Hollianne","Spitters, Christopher","Ericson, Keith","Wilkerson, Sara","Tural, Ahmet","Diaz, George","Cohn, Amanda","Fox, LeAnne","Patel, Anita","Gerber, Susan I","Kim, Lindsay","Tong, Suxiang","Lu, Xiaoyan","Lindstrom, Steve","Pallansch, Mark A","Weldon, William C","Biggs, Holly M","Uyeki, Timothy M","Pillai, Satish K","32004427"],"abstract":["An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient's initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection."],"journal":"N Engl J Med","authors":["Holshue, Michelle L","DeBolt, Chas","Lindquist, Scott","Lofy, Kathy H","Wiesman, John","Bruce, Hollianne","Spitters, Christopher","Ericson, Keith","Wilkerson, Sara","Tural, Ahmet","Diaz, George","Cohn, Amanda","Fox, LeAnne","Patel, Anita","Gerber, Susan I","Kim, Lindsay","Tong, Suxiang","Lu, Xiaoyan","Lindstrom, Steve","Pallansch, Mark A","Weldon, William C","Biggs, Holly M","Uyeki, Timothy M","Pillai, Satish K"],"date":"2020-02-01T11:00:00Z","year":2020,"_id":"32004427","source":"PubMed","week":"20205|Jan 27 - Feb 02","doi":"10.1056/NEJMoa2001191","link_comment_in":"32320565","locations":["Wuhan","China","United States","United States"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138493061955586,"score":106.01458},{"pmid":32056397,"pmcid":"PMC7039714","title":"Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic Findings in Two Cases.","text":["Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic Findings in Two Cases.","Since the 2019 novel coronavirus (2019-nCoV or officially named by the World Health Organization as COVID-19) outbreak in Wuhan, Hubei Province, China in 2019, there have been a few reports of its imaging findings. Here, we report two confirmed cases of 2019-nCoV pneumonia with chest computed tomography findings of multiple regions of patchy consolidation and ground-glass opacities in both lungs. These findings were characteristically located along the bronchial bundle or subpleural lungs.","Korean J Radiol","Lin, Xiaoqi","Gong, Zhenyu","Xiao, Zuke","Xiong, Jingliang","Fan, Bing","Liu, Jiaqi","32056397"],"abstract":["Since the 2019 novel coronavirus (2019-nCoV or officially named by the World Health Organization as COVID-19) outbreak in Wuhan, Hubei Province, China in 2019, there have been a few reports of its imaging findings. Here, we report two confirmed cases of 2019-nCoV pneumonia with chest computed tomography findings of multiple regions of patchy consolidation and ground-glass opacities in both lungs. These findings were characteristically located along the bronchial bundle or subpleural lungs."],"journal":"Korean J Radiol","authors":["Lin, Xiaoqi","Gong, Zhenyu","Xiao, Zuke","Xiong, Jingliang","Fan, Bing","Liu, Jiaqi"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32056397","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.3348/kjr.2020.0078","keywords":["2019 novel coronavirus","computed tomography","severe acute respiratory infection"],"link_comment_in":"32174056","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138492991700992,"score":100.76821},{"pmid":32436460,"title":"TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.","text":["TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.","Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFalpha, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. The reviews of this paper are available via the supplemental material section.","Ther Adv Respir Dis","Chen, Xue-Yan","Yan, Bing-Xi","Man, Xiao-Yong","32436460"],"abstract":["Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFalpha, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. The reviews of this paper are available via the supplemental material section."],"journal":"Ther Adv Respir Dis","authors":["Chen, Xue-Yan","Yan, Bing-Xi","Man, Xiao-Yong"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436460","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1753466620926800","keywords":["covid-19","tnfalpha inhibitor","etanercept","toxic epidermal necrolysis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393816764416,"score":96.94402},{"pmid":32445935,"title":"Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy.","text":["Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy.","OBJECTIVE: The aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular chronic inflammatory arthritides. METHODS: To this end, a population-based study, in the province of Udine (466,700 inhabitants, with age > 15 years old, Friuli Venezia Giulia region, Italy) was planned. The primary outcome was the prevalence of COVID-19 in the first two months of the outbreak. All the rheumatic patients treated with biologic agents or small molecules in the last 6 months in our province were included (N=1051). RESULTS: From February 29 to April 25, 2020, 4 adult patients (4/1051, i.e. 3.8/1000, 95% Confidence Interval 1.5-9.7/1000) were registered as swab test positive by PCR for COVID-19. Overall, a total of 47/1051 (4,5%) cases were tested for COVID-19 by PCR in the same period, and 15 of them due to symptoms compatible with COVID-19. In the general population, the prevalence was 937 cases/466700 (2/1000, 95% Confidence Interval 1.9-2.1/1000, p value=0.33, chi square test), and 20,179/466,700 (4.3%) swab tests for COVID-19 were performed.. CONCLUSION: The risk of COVID-19 in rheumatic patients under biologic agents or small molecules does not appear different from that observed in the general population. Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19.","Joint Bone Spine","Quartuccio, Luca","Valent, Francesca","Pasut, Enrico","Tascini, Carlo","Vita, Salvatore De","32445935"],"abstract":["OBJECTIVE: The aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular chronic inflammatory arthritides. METHODS: To this end, a population-based study, in the province of Udine (466,700 inhabitants, with age > 15 years old, Friuli Venezia Giulia region, Italy) was planned. The primary outcome was the prevalence of COVID-19 in the first two months of the outbreak. All the rheumatic patients treated with biologic agents or small molecules in the last 6 months in our province were included (N=1051). RESULTS: From February 29 to April 25, 2020, 4 adult patients (4/1051, i.e. 3.8/1000, 95% Confidence Interval 1.5-9.7/1000) were registered as swab test positive by PCR for COVID-19. Overall, a total of 47/1051 (4,5%) cases were tested for COVID-19 by PCR in the same period, and 15 of them due to symptoms compatible with COVID-19. In the general population, the prevalence was 937 cases/466700 (2/1000, 95% Confidence Interval 1.9-2.1/1000, p value=0.33, chi square test), and 20,179/466,700 (4.3%) swab tests for COVID-19 were performed.. CONCLUSION: The risk of COVID-19 in rheumatic patients under biologic agents or small molecules does not appear different from that observed in the general population. Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19."],"journal":"Joint Bone Spine","authors":["Quartuccio, Luca","Valent, Francesca","Pasut, Enrico","Tascini, Carlo","Vita, Salvatore De"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445935","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jbspin.2020.05.003","keywords":["covid-19","biologic","coronavirus","rheumatic disease","rheumatoid arthritis","small molecule","tumor necrosis factor"],"locations":["Italy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1667600475830091776,"score":95.090904}]}